Shionogi sets up manufacturing subsidiary

Japanese drug major Shionogi (TYO: 4507) is to establish a new subsidiary in its native country to take on the group’s manufacturing functions.

The subsidiary, which has not yet been named, promises to carry out Shionogi’s manufacturing of medicines using the latest technology and to contribute to the growth of the pharmaceutical industry in Japan by developing contract businesses including manufacture of investigational drug products, analytical testing, pharmaceutical engineering, as well as commercial contract pharmaceutical manufacturing, all benefiting from the experience and expertise of the new company.

Better known historically for its focus on its key areas of infectious diseases and pain, Shionogi’s targeting of other therapy areas where there is high medical need is evidenced by a recently agreed psychiatric disorders collaboration. Its other research includes work in chronic liver disease, obesity and oncology.